In AML, CSF3R mutations were more frequent in patients harboring core-binding factor (CBF) alterations (25%) and CEBPA mutations (11.8%), followed by AML with MDS-related alterations (mutations or cytogenetic abnormalities) (7.5%), NPM1 mutated AML (7.4%) and AML harboring TP53 mutations and/or 17p deletion (6.9%) (Table 1 and Supplementary Table 1). This evidence concerns the gene CSF3R and acute myeloid leukemia.